Patent 7666990 was granted and assigned to Canadian Blood Services on February, 2010 by the United States Patent and Trademark Office.
There is provided FV derivatives that reduce blood clotting activity, by reducing thrombin generation, when compared to wild-type FV. In particular, the FV of the present invention comprises single-point and multi-point mutations, encompassed by aspartic acid 79 to glutamic acid 119 of the wild type sequence (SEQ ID NO:2). The derivatives can be used to treat patient with conditions necessitating reduced clotting activity.